Thrombocytosis is a marker of reduced survival in patients with renal cell carcinoma.

A multicenter study.

Abstract

Introduction: Thrombocytosis occurs as an inflammatory bone marrow response in the presence of chronic diseases, generally infectious. The association of thrombocytosis and its prognostic impact on survival in patients with renal cell carcinoma (RCC) has not been definitively established. This study aimed to determine survival rates in two reference centers in Quito-Ecuador for treating patients with RCC.

Methods: The present longitudinal study was conducted at the "Carlos Andrade Marín" Specialty Hospital and the General Specialty Hospital Number 1, in Quito-Ecuador, from January 2005 to December 2016. Patients with CRC at one year of age were included. Survival since nephrectomy was determined. Mortality, age, staging, and survival were determined. Two groups with the presence or absence of thrombocytosis were analyzed. The sample was probabilistic. Survival analysis is performed using the Kaplan-Meier method, and a COX regression is performed on the associated variables.

Results: 183 patients, 62.2 ± 12.8 years old, were included. There were 132 cases (72.1%) of localized CRC, 35 cases (19.1%) of advanced stage, and 16 cases (8.7%) of the metastatic stage. The mean number of platelets was 300020 ±102300 u/ul. Fifty patients (27.3%) presented thrombocytosis. Overall survival of the group with thrombocytosis was 50.4 (38.2-62.6) months versus 68.1 (60.8-75.3) months in the group without thrombocytosis, P<0.005.